Human trial
Primary evidence or regulator source
95 adults in crossover studies
Reported findings. Increased reproductive hormones
Nonresponse. No significant anxiety effect
Harms. Long-term treatment safety not established
Limits. No transfer to other routes/formulations/indications; clinician review pending.
Preparation: Kisspeptin-54, not automatically kisspeptin-10 Route: intravenous
Read original source ↗Editorial review 2026-10-09. Clinician review pending.